Obviousness

Analysis of Obviousness for U.S. Patent 12,403,095 under 35 U.S.C. § 103

An analysis of U.S. Patent 12,403,095 for obviousness under 35 U.S.C. § 103 reveals that claims 1 and 11, the independent claims, appear to be rendered obvious by a combination of the prior art, primarily European Patent No. 2575769 B1 (EP '769), in conjunction with a person having ordinary skill in the art's (POSITA) general knowledge of pharmaceutical formulation and regulatory requirements.

Identified Combinations and Rationale for Obviousness

The most potent combination for challenging the obviousness of claims 1 and 11 is EP 2575769 B1 alone, or in combination with general pharmaceutical knowledge.

EP 2575769 B1 (Veloxis Pharmaceuticals A/S)

• Relevance: This European patent, from the same assignee as US 12,403,095, is highly relevant as it explicitly discloses stabilized pharmaceutical compositions of tacrolimus. It describes a solid dispersion of tacrolimus with a stabilizing agent to prevent the formation of degradation products, including 8-epitacrolimus. It also mentions using organic acids like tartaric acid as stabilizing agents and provides examples of compositions with polyethylene glycol (PEG) 6000 and poloxamer 188 as the vehicle. Crucially, it discloses stability data after storage at 25°C/60% RH.

Addressing Limitations of Claims 1 and 11 with EP '769:

1. Solid Dispersion of Tacrolimus in a Vehicle with a Stabilizing Agent: EP '769 explicitly teaches this core concept.
2. Stabilizing Agent is a Metal Chelating Agent and Provides a pH Below 7: EP '769 discloses the use of organic acids, specifically tartaric acid, as a stabilizing agent. A POSITA would readily know that tartaric acid is a dicarboxylic acid, capable of lowering pH and acting as a metal chelating agent. The US 12,403,095 patent itself notes that "tartaric acid has a chelating effect. It is contemplated that a chelator stabilizing agent is preferred in order to prevent or reduce formation of C8-epimer tacrolimus degradation product." Furthermore, the '095 patent states that "the pH may be provided by the stabilizing agent and/or be adjusted by an inorganic or organic acid or a mixture thereof," and explicitly shows tartaric acid providing a pH of 3.5. This demonstrates that the pH-lowering and chelating properties are inherent or well-known aspects of using tartaric acid for stabilization against 8-epitacrolimus.
3. Tacrolimus Concentration (0.5% to 5% w/w): US 7,994,214 B2 (Holm et al.), which shares an inventor with the '095 patent, discloses tacrolimus concentrations from 0.01% to 15% w/w in solid dispersions, encompassing the claimed range. This range would be well within the knowledge of a POSITA, especially one working for Veloxis Pharmaceuticals.
4. Tacrolimus is the Sole Active Ingredient: When formulating a specific drug like tacrolimus for its known immunosuppressive purpose, it is standard pharmaceutical practice to develop formulations where it is the sole active ingredient, unless a specific combination therapy is explicitly intended. EP '769's disclosure of "stabilized pharmaceutical compositions of tacrolimus" would inherently imply such formulations.
5. Vehicle Does Not Include a Cyclo-dextrin: EP '769 provides examples of vehicles such as PEG 6000 and poloxamer 188. These are not cyclodextrins. The '095 patent itself lists cyclodextrins as other useful hydrophilic or water-miscible vehicles, indicating they are not universally required. Thus, excluding cyclodextrins would not represent an inventive step if the core stabilization mechanism relies on other vehicle components.
6. Specific Quantitative Stability Limits for 8-epitacrolimus: This is the most specific limitation. The '095 patent defines limits such as "no more than 0.5% more 8-epitacrolimus after storage at 40° C. at 75% relative humidity for 5 weeks" (Claim 1) or "no more than 0.2% more 8-epitacrolimus after storage at 25° C. at 60% relative humidity for 5 weeks" (Claim 11).
   • The '095 patent highlights that the International Conference of Harmonization (ICH) guidelines set a limit of 0.5% for a single degradation product for daily dosages between 10 to 100 mg. A POSITA would be strongly motivated to achieve stability profiles that meet these known regulatory standards.
   • EP '769 already discloses stability data at 25°C/60% RH, one of the storage conditions. If the data in EP '769 demonstrates improved stability of tacrolimus and reduced 8-epitacrolimus, a POSITA would find it obvious to optimize the concentration of the stabilizing agent (e.g., tartaric acid) to meet or exceed these regulatory thresholds. Example 8 of the '095 patent itself demonstrates the routine optimization of tartaric acid concentration to achieve "long term stability" and identifies an "optimum" range of 0.10% to 0.20% w/w for the highest stabilizing effect. Such optimization would be considered routine experimentation for a formulator seeking to enhance product shelf-life and regulatory compliance.

Motivation to Combine:

A POSITA, particularly one associated with Veloxis Pharmaceuticals (due to the shared assignee and inventors between EP '769 and US 12,403,095), would be well aware of the challenges in stabilizing tacrolimus and the problem of 8-epitacrolimus formation. EP '769 directly addresses this by teaching a solution: using organic acid chelators in a solid dispersion to prevent 8-epitacrolimus. The motivation to further develop or optimize these formulations to meet specific, known regulatory impurity limits (like those from ICH guidelines) would be high. The adjustments to the concentration of the stabilizing agent to achieve precise stability outcomes, as well as the selection of commonly known vehicles (like PEG and poloxamer) without adding non-essential components (like cyclodextrins), would be considered within the ordinary skill of a formulator.

Therefore, the combination of the specific teachings of EP 2575769 B1 regarding tacrolimus solid dispersions, stabilizing agents (e.g., tartaric acid), and their effect on 8-epitacrolimus, with the general knowledge of pharmaceutical formulation and the goal of meeting established regulatory stability criteria, would have made claims 1 and 11 of US 12,403,095 obvious to a POSITA.